The Nairobi Hospital has named a former Vice President of Global Health at GlaxoSmithKline (GSK) as its new chief executive.
Dr Allan Pamba will focus on driving business strategy, revenue and investment growth.
He takes over from Christopher Abeid who was CEO in an acting capacity until April last year when the then CEO Gordon Odundo was fired.
According to his LinkedIn page, Pamba describes himself as a “Passionate Global Health Expert with a unique mix of professional experiences; Robust Research and development (R&D), Commercial Strategy & Execution, Government Affairs & External Relations experience in the Pharmaceutical Industry. “
He began his career with GSK in R&D, leading programmes that contributed to the development of the first malaria vaccine as well as the most progressive treatment for Vivax Malaria to date, Tafenoquine.
Africa Shared Value Summit in his speaker profile, they stated that when serving as Vice-President & General Manager of GSK’s pharmaceuticals business across East Africa, as well as Government Affairs across Africa, “ He delivered business growth hand in hand with public health impact.
Most significantly, he inspired and negotiated new vaccine introductions, for example, the introduction of the Rotavirus vaccine in Rwanda, Uganda and the DRC, impacting the lives of millions of children for decades to come.”
Pamba holds a Master of Science degree in Public Health and two bachelor’s degrees in Medicine and Surgery both from Moi University.